Millions of dollars are spent on the development of biomaterials, with many put into animal and clinical studies without proper evaluation, often leading to unfavourable outcomes and associated patient morbidity
— Procedia Engineering (2013) 53:138-43

Why to do BEST?

  • All medical devices, based on biomaterials, combined medicinal products, and tissue derivatives, must demonstrate regulative conformity (EU MDR 2017/745). The conformity assessment of a biomaterial depends on its clinical application, conditions and requirements.

BEST is implemented on special equipment and with algorithms for evaluation in a way to respond as much as possible to the clinical targets.

  • It is vitally important to reduce risk/benefit ratio, improve patient safety and decreasing the lead time and costs at R&D and production. See what BEST already did for these cases.

BEST excels existing, often oversimplified, protocols and provides tangible outcomes promoting translation from bench to bedside.

  • Reduction, refinement and replacement (the "3R") of animal testing is one of the modern development in medical technology (2010/63/EC).

BEST targets on full deployment of alternative methods ("not tested on animals").


BEST applications span many medical and clinical applications with a great variety of the functionality, optimization and risk assessment actions:

  • 3D bioprinting

  • ATMP solutions

  • Anti-bacterial

  • Cancer

  • Cardiac

  • Cosmetic

  • Dental

  • Endocrine

  • Gynaecologic

  • Immunologic

  • Implants

  • Injectables development

  • Joints repair

  • Neurologic

  • Ophthalmic

  • Orthobiology

  • Orthopaedic

  • Pharmaceutics

  • Plastic surgery

  • Pulmonologic

  • Scaffolds

  • Soft tissues

  • Stem cells

  • Spinal / IVD

  • Surgical

  • Urologic

  • Veterinary